Dec. 15, 2025—Werfen announced its commendation of the publication of a special report underscoring the urgent need to address the risks of undetected in vitro hemolysis (Wu AHB, et al. J Appl Lab Med. 2025;10[5]:1347–1361).
The report advocates for a coordinated, hospitalwide approach to better detect, prevent, and manage in vitro hemolysis, particularly in high-risk settings such as emergency departments and intensive care units. It highlights hemolysis as a significant cause of preanalytical error, with the potential to cause misinterpretation of critical results, most notably potassium.
“This important publication highlights the prevalence and risks of undetected hemolysis in whole blood samples, which can impact test results throughout the hospital,” Annie Winkler, MD, CMO at Werfen, said in a company press release. “With innovative technology that detects hemolysis at the point of care in seconds, we can help hospitals expedite decision-making, enhance efficiency, and most importantly, improve patient management.”
Werfen disclosed that it has previously contributed to research funding for one of the authors, and several authors disclosed relationships with Werfen, among other companies. Werfen’s Gem Premier 7000 with iQM 3 detects hemolysis at the point of care in 45 seconds.